Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Readers Comments

 Back to Item »

Harvard Professor Rides Genomics' Third Wave

New Firm Aims to Advance Personalized Medicine through Precision Diagnostics

1 Readers' Comments

Posted by: Michael Lerman

07/06/2012

I knew prof Boguski when he was in NCBI. Precision diagnostics is the patients tumor genome sequence (which at this time will not be accurate) and its functional analysis. This will take time and will be costly especially the sequence interpretation.
Now in cancer mutated driver genes will be found but the promise of "more targeted therapy" is greatly exaggerated as no targets were found in as many as ~200 tumors (Vogelsten). With all due respect there is to much over-promising the company is offering. The personalized treatment in case of cancer is a dream for the future

  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll